No Data
No Data
Qualigen Therapeutics, Inc. Receives Notification of Deficiency From Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
Qualigen Therapeutics Signs MoU To Acquire Marizyme, Stock Down In Pre-Market
Qualigen Enters $10B Coronary Artery Bypass Graft Market With Non-Binding MOU To Acquire Marizyme
Express News | Qualigen Seeks to Enter the $10 Billion Cabg Market With Non-Binding Mou to Acquire Marizyme
Qualigen Seeks To Enter The $10 Billion CABG Market With Non-binding MOU To Acquire Marizyme >QLGN
Qualigen to Participate in Next Funding Round for NanoSynex
Mimi888 : Thank you always Dr.J
105181423 : Thank you, boss.
jimmy the trader : thanks J
かつやっチョッ : Thank you, teacher
I appreciate it 